About
About rybelsus.life
An independent guide to the first GLP-1 tablet, for the people who take it and the people deciding whether to.
Why this site exists
Rybelsus is the same medicine under different names, doses, prices and rules depending on where you live. In 2026 alone it was renamed in the United States, moved to new tablet strengths in several countries, and gained two new tablet rivals. The official information is accurate but scattered across regulators, manufacturers and health services. We bring it together, country by country, and keep it current.
Who we are
rybelsus.life is published by Hix Digital Ltd, a small UK digital publisher. We are not a pharmacy, a clinic or a drug company, and we have no connection with Novo Nordisk or Eli Lilly. The name describes what the site is about; it does not mean the site is official.
What we do not do
- We do not sell medicines or take orders.
- We do not give personal medical advice. Your prescriber and pharmacist know your history; we do not.
- We do not list sellers who supply prescription medicines without a prescription.
- We do not accept payment to appear in a directory or to change what we write.
Getting in touch
Spotted something out of date or wrong? We want to know. See contact. How we research and write is set out in our editorial policy, and how the site is funded in how we make money.